CLEC12A/MICL/CLL-1 HFc Chimera[Biotin], Avi, Human

Immobilized Anti-CLEC12A Antibody, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human with the EC50 of 25.8 ng/ml determined by ELISA.

The purity of CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human is greater than 95% as determined by SEC-HPLC.

CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.

产品编号	Z03960
规格	100 μg 500 μg 大单询价
数量
价格	￥5700


联系我们

产品简介

Species

Human

Protein Construction

Avi	hFc	CLEC12A/MICL/CLL-1 (His65-Ala265) Accession # Q5QGZ9-2
N-term		C-term

Conjugate

Biotin

Purity

> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Immobilized Anti-CLEC12A Antibody, hFc Tag at 1 μg/ml (100μl/Well) on the plate can bind CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human (Cat.No.: Z03960)

Expression System

HEK293

Theoretical Molecular Weight

51.7 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 67-70 kDa based on Bis-Tris PAGE result.

Formulation

Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).

Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 μg/ml.

Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

图例

The purity of CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human is greater than 95% as determined by SEC-HPLC.

CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

技术背景

Target Background

CLEC12A, also known as CLL-1 is inhibitory C-type lectin-like receptor with ITIM motif. It can associate with signaling phosphatases SHP-1 and SHP-2. CLEC12A is a potential target due to its high expression in acute myeloid leukemia (AML) cells. And there are various therapeutic approaches using CLEC12A as a target for AML, such as CD3/ CLEC12A antibody. It can recruit unstimulated primary T cells against cancer cells with CLL-1 on the surface.

Synonyms

MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human

资源中心

技术支持

关于我们